Dyadic International (DYAI) Enterprise Value (2017 - 2026)
Dyadic International's (DYAI) quarterly Enterprise Value came in at $21.9 million in Q1 2026, down 34.12% year-over-year from $33.3 million in Q1 2025, and down 3.52% quarter-over-quarter from $22.7 million in Q4 2025.
Analysis
Dyadic International (DYAI) Enterprise Value (2017 - 2026) Analysis & Trends
Dyadic International has disclosed Enterprise Value across 10 years of filings, most recently posting $21.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 34.12% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $21.9 million (down 34.12% YoY), while the FY2025 annual figure was $22.7 million, down 47.11% from the prior year.
- Enterprise Value came in at $21.9 million for Q1 2026 at Dyadic International, down from $22.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $70.6 million in Q2 2022 to a low of -$15.4 billion in Q1 2022.
- Average Enterprise Value over 5 years is -$870.2 million, with a median of $33.5 million recorded in 2024.
- Year-over-year, Enterprise Value sank 12479.15% in 2022 and soared 100.26% in 2023.
- Over 5 years, Enterprise Value stood at $22.5 million in 2022, then soared by 73.95% to $39.1 million in 2023, then climbed by 9.78% to $42.9 million in 2024, then slumped by 47.11% to $22.7 million in 2025, then declined by 3.52% to $21.9 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were $21.9 million in Q1 2026, $22.7 million in Q4 2025, and $29.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 21.92 Mn |
| Dec 31, 2025 | 22.72 Mn |
| Sep 30, 2025 | 29.20 Mn |
| Jun 30, 2025 | 15.63 Mn |
| Mar 31, 2025 | 33.27 Mn |
| Dec 31, 2024 | 42.95 Mn |
| Sep 30, 2024 | 20.85 Mn |
| Jun 30, 2024 | 33.53 Mn |
| Mar 31, 2024 | 36.70 Mn |
| Dec 31, 2023 | 39.12 Mn |
| Sep 30, 2023 | 47.14 Mn |
| Jun 30, 2023 | 45.48 Mn |
| Mar 31, 2023 | 39.55 Mn |
| Dec 31, 2022 | 22.49 Mn |
| Sep 30, 2022 | 40.16 Mn |
| Jun 30, 2022 | 70.57 Mn |
| Mar 31, 2022 | -15.36 Bn |
| Dec 31, 2021 | 107.34 Mn |
| Sep 30, 2021 | 133.37 Mn |
| Jun 30, 2021 | 75.20 Mn |